Thus, we sought to investigate whether microenvironmental cytokines, released by cancer-associated fibroblasts (CAFs), would affect the viability of CR-CSphCs treated with dinaciclib-based therapy, which targets downstream of the MEK pathway. The gene discussed is MAP2K7; the disease is cancer.